The Dose Reduction in Schizophrenia (DORIS) study: A final report

J. Hirschowitz, Robert Hitzemann, K. Piscani, G. Burr, E. Frecska, D. Culliton, M. Mann, C. Curtis

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

Twenty-one medication-free chronic schizophrenics were randomly assigned to three treatment groups: 50% blockade of the bromocriptine growth hormone (GH) response, 100% blockade or 10 ng/ml haloperidol. Only seven of the 21 patients showed a significant improvement after 6 weeks in positive psychotic symptoms; six of the seven responders came from the 50 and 100% blockade groups, suggesting greater efficacy at lower doses. Fifty percent blockade was associated with an average daily haloperidol dose of 3.2 mg and plasma haloperidol levels below the limit of detection (

Original languageEnglish (US)
Pages (from-to)31-43
Number of pages13
JournalSchizophrenia Research
Volume23
Issue number1
DOIs
Publication statusPublished - Jan 17 1997
Externally publishedYes

    Fingerprint

Keywords

  • bromocriptine
  • dose reduction
  • growth hormone
  • haloperidol
  • positive symptoms
  • psychosis
  • schizophrenia

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Behavioral Neuroscience
  • Biological Psychiatry
  • Neurology
  • Psychology(all)

Cite this

Hirschowitz, J., Hitzemann, R., Piscani, K., Burr, G., Frecska, E., Culliton, D., ... Curtis, C. (1997). The Dose Reduction in Schizophrenia (DORIS) study: A final report. Schizophrenia Research, 23(1), 31-43. https://doi.org/10.1016/S0920-9964(96)00074-6